Catalyst
Slingshot members are tracking this event:
Topline results released for Novartis' (NVS) Phase III study of ACZ885 (canakinumab) in reducing cardiovascular risk in people who survived a heart attack
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 22, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Acz885, Canakinumab, Heart Attack, Cardiovascular Risk
